Life Science’s continued organic growth gave Merck’s Q1 figures the right impetus, but profitability clearly fell apart as Health Care lagged the previous year’s milestone and saw some pre-launch costs for Bavencio and Mavenclad. Performance Materials faced a slightly faster leave from its liquid crystal’s paradise, which was partly dampened by supportive OLED sales. The higher than expected hedging losses were an additional burden. EBITDA before one-offs came in below
14 May 2019
Uplifting Life Science, but burdening one-offs
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Uplifting Life Science, but burdening one-offs
Merck KGaA (MRCK:WBO) | 0 0 1.2% | Mkt Cap: 10,792m
- Published:
14 May 2019 -
Author:
Martin Schnee -
Pages:
3
Life Science’s continued organic growth gave Merck’s Q1 figures the right impetus, but profitability clearly fell apart as Health Care lagged the previous year’s milestone and saw some pre-launch costs for Bavencio and Mavenclad. Performance Materials faced a slightly faster leave from its liquid crystal’s paradise, which was partly dampened by supportive OLED sales. The higher than expected hedging losses were an additional burden. EBITDA before one-offs came in below